Lamivudine therapy for chronic hepatitis B in renal transplant recipients

European Journal of Gastroenterology and Hepatology

Volumn 16, Issue 12, 2004, Pages 1261-1264

  Durlik, Magdalena ^a   Lewandowska, Dorota ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Hepatitis B; Lamivudine; Renal transplantation

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; INTERFERON; LAMIVUDINE;

CHRONIC HEPATITIS; GENE LOCUS; GRAFT SURVIVAL; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; SHORT SURVEY; STRUCTURAL GENE; VIRUS REPLICATION;

HEPATITIS B, CHRONIC; HUMANS; KIDNEY TRANSPLANTATION; LAMIVUDINE; POSTOPERATIVE CARE; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME;

EID: 10344227777     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200412000-00004     Document Type: Short Survey

References (25)

1. Fabrizi F, Martin P, Ponticelli C. Hepatitis B virus and renal transplantation. Nephron 2002; 90:241-251.
2. Tur-Kaspa R, Burk R, Shaul Y, Shafritz D. Hepatitis B virus DNA contains a glucocorticoid responsive element. Proc Natl Acad Sci USA 1986; 83:1627.
3. Kletzmayr J, Watschinger B. Chronic hepatitis B virus infection in renal transplant recipients. Semin Nephrol 2002; 22:375-389.
4. Younossi Z, Braun W, Protiva D, Gifford R, Straffon RA. Chronic viral hepatitis in renal transplant recipients with allograft functioning for more than 20 years. Transplantation 1999; 67:272-275.
5. Fornairon S, Pol S, Legendre C, Carrot F, Memzer-Breneel MF, Brechot C, Kreis H. The long-term virologic and pathologic impact of renal transplantation on chronic hepatitis B virus infection. Transplantation 1996; 62:297-299.
6. Rao KV, Kasiske BL, Anderson WR. Variability and morphological spectrum and clinical outcome of chronic liver disease in hepatitis B-positive and B-negative renal transplant recipients. Transplantation 1991; 51:391-396.
7. Mathurin P, Mouquet C, Poynard T, Sylla C, Benalia H, Fretz C, et al. Impact of hepatitis B and C virus on kidney transplant outcome. Hepatology 1999; 29:257-263.
8. Gane E, Pilmore H. Management of chronic viral hepatitis before and after renal transplantation. Transplantation 2002; 74:427-437.
9. BPG Expert Group on Renal Transplantation. European Best Practice Guidelines for Renal Transplantation (part 1). Nephr Dial Transplant 2000; 15 (suppl 7):9-11.
10. Kasiske BL, Vazquez MA, Harmon WE, Brown RS, Danovitch GM, Gaston R, et al. Recommendation for the outpatient surveillance of renal transplant recipients. J Am Soc Nephrol 2000; 11:1-86.
11. Rostaing L, Henry S, Cisterne JM, Duffaut M, Icart J, Durand D. Efficacy and safety of lamivudine on replication of recurrent hepatitis B after cadaveric renal transplantation. Transplantation 1997; 64:1624-1627.
12. Kletzmayr J, Watschinger B, Muller C, Demetriou D, Puchhammer-Stockl E, Ferenci P, et al. Twelve months of lamivudine treatment for chronic hepatitis B virus infection in renal transplant recipients. Transplantation 2000; 70:1404-1407.
13. Lee WC, Wu MJ, Cheng CH, Chen CH, Shu KH, Lian JD. Lamivudine is effective for the treatment of reactivation of hepatitis B virus and fulminant hepatic failure in renal transplant recipients. Am J Kidney Dis 2001; 38:1074-1081.
14. Lewandowska D, Durlik M, Kukula K, Cieciura T, Ciecierski R, Walewska-Zielecka B, et al. Treatment of chronic hepatitis B with lamivudine in renal allograft recipients. Transplant Proc 2000; 32:1369-1370.
15. Mosconi G, Scolari MP, Manna C, Canova C, Cristino S, Campieri C, et al. Lamivudine in recurrent hepatitis C after renal transplantation. Transplant Proc 2001; 33:1873-1874.
16. Mouquet C, Bernard B, Poynard T, Thibault V, Opolon P, Coriat P, et al. Chronic hepatitis B treatment with lamivudine in kidney transplant patients. Transplant Proc 2000; 32:2762.
17. Park SK, Yang WS, Lee YS, Jung HH, Chang JW, Choi HJ, et al. Outcome of renal transplantation in hepatitis B surface antigen-positive patients after introduction of lamivudine. Nephrol Dial Transplant 2001; 16:2222-2228.
18. Fabrizi F, Dulai G, Dixit V, Bunnapradist S, Martin P. Lamivudine for treatment of hepatitis B virus-related liver disease after renal transplantation: meta-analysis of clinical trials. Transplantation 2004; 77:859-864.
19. Tassopoulos NC, Volpes R, Pastore G, Heathcote J, Buti J, Goldin R, et al. Efficacy of lamivudine in patients with hepatitis Be antigen-negative/ hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Hepatology 1999; 29:889-896.
20. Al Faraidy K, Yoshida EM, Davis JE, Vartanian RK, Anderson FH, Steinbrecher UP. Alteration of the dismal natural history of fibrosing cholestatic hepatitis secondary to hepatitis B virus with the use of lamivudine. Transplantation 1997; 64:926-928.
21. Han DJ, Kim TH, Park SK, Kim SB, Yang WS, Park JS, et al. Results on preemptive or prophylactic treatment of lamivudine in HBsAg(+) renal allograft recipients: comparison with salvage treatment after hepatic dysfunction with HBV recurrence. Transplantation 2001; 71:387-394.
22. Jung S, Lee HC, Han JM, Lee YJ, Chung YH, Lee YS, et al. Four cases of hepatitis B virus-related fibrosing cholestatic hepatitis treated with lamivudine. J Gastroenterol Hepatol 2002; 17:345-350.
23. Nakhoul F, Gelman R, Green J, Khankin E, Baruch Y. Lamivudine therapy for severe acute hepatitis B virus infection after renal transplantation: case report and literature review. Transplant Proc 2001; 33:2948-2949.
24. Chan TM, Fang GX, Tang CS, Cheng IK, Lai KN, Ho SK. Pre-emptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients. Hepatology 2002; 36:1246-1252.
25. Tsai MK, Lai MY, Hu RH, Lee CJ, Lee PH. Managing hepatitis B reactivation in renal transplant recipients: a 12 year review with emphasis on early detection and early use of lamivudine. Transplant Proc 2000; 32:1935-1936.